Results 81 to 90 of about 12,300 (184)

Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation

Annals of Neurology, Volume 99, Issue 4, Page 976-988, April 2026.
Objective Whether cognitive decline in patients with Parkinson's disease (PD) carrying GBA1 variants is accelerated after subthalamic deep brain stimulation (STN‐DBS) remains controversial. Clarifying long‐term cognitive outcomes is essential for informed decision making.
Moritz A. Loeffler, Philipp Klocke, Isabel Wurster, Stefanie Lerche, Idil Cebi, Thomas Gasser, Alireza Gharabaghi, Kathrin Brockmann, Daniel Weiss   +8 more
wiley   +1 more source

Epidemiology and Genetics of Rheumatic Diseases Suggest a Constant Rate of DNA Damage as Underlying Cause

Immunology, Volume 177, Issue 4, Page 736-748, April 2026.
A constant rate of DNA damage that is not perfectly repaired will cause a constant rate of DNA mutations. The chance of mutation will increase if DNA is prone to damage, such as occurs in somatic hypermutation (SHM) hotspots and GC‐rich DNA. Thus, if one mutation‐prone DNA site drives disease, the age of onset of disease and degree of penetrance should
Piet C. de Groen
wiley   +1 more source

Neuronal activity triggers secretory autophagy to mediate the extracellular release of SNCA/α-synuclein

Autophagy Reports
Autophagy has two distinct pathways, degradation and secretion. Autophagic degradation plays a pivotal role in cellular homeostasis by the formation of a double-membrane autophagosome in concert with numerous ATG (autophagy-related) proteins.
Yoshitsugu Nakamura, Shigeki Arawaka
doaj   +1 more source

Genetic Variants in SNCA and the Risk of Sporadic Parkinson’s Disease and Clinical Outcomes: A Review

Parkinson's Disease, 2017
There is increasing evidence of the contribution of genetic susceptibility to the etiology of Parkinson’s disease (PD). Genetic variations in the SNCA gene are well established by linkage and genome-wide association studies.
Clarissa Loureiro das Chagas Campêlo, Regina Helena Silva   +1 more
doaj   +1 more source

Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse

Neurobiology of Disease, 2014
Parkinson's disease (PD) is a neurodegenerative disorder classically characterized by the death of dopamine (DA) neurons in the substantia nigra pars compacta and by intracellular Lewy bodies composed largely of α-synuclein.
Tonya N. Taylor, Dawid Potgieter, Sabina Anwar, Steven L. Senior, Stephanie Janezic, Sarah Threlfell, Brent Ryan, Laura Parkkinen, Thierry Deltheil, Milena Cioroch, Achilleas Livieratos, Peter L. Oliver, Katie A. Jennings, Kay E. Davies, Olaf Ansorge, David M. Bannerman, Stephanie J. Cragg, Richard Wade-Martins   +17 more
doaj   +1 more source

Vitamin D Regulates Olfactory Function via Dual Transcriptional and mTOR‐Dependent Translational Control of Synaptic Proteins

Advanced Science, Volume 13, Issue 13, 3 March 2026.
Vitamin D (VitD) modulates olfactory function by remodeling dendrodendritic synapses in tufted cells through vitamin D receptor‐dependent transcriptional and translational mechanisms. VitD regulates synaptic protein translation partially via mTOR signaling.
Pengcheng Ren, Renhe Cao, Xiaoshan Ye, Wenbin Pang, Qingshang Bi, Meihui Huang, Qionglin Zhou, Dan Ye, Wei Xiang, Le Xiao   +9 more
wiley   +1 more source

Understanding Neurodegenerative Diseases From the −Omics Perspective: Lessons Learnt

Annals of Neurology, Volume 99, Issue 3, Page 566-587, March 2026.
[Color figure can be viewed at www.annalsofneurology.org] As the population ages, certain neurodegenerative diseases (NDs) are becoming a major health issue. For this reason, this review will focus on the most common ND with onset after 65 years old; Alzheimer's disease, Parkinson's disease, Lewy body dementia, and frontotemporal dementia.
Laura Ibanez, Cyril Pottier, Aleksandra Beric, Daniel Western, Muhammad Ali, Carlos Cruchaga   +5 more
wiley   +1 more source

SYNGR3 Accelerates α‐Synuclein Aggregation and Neurodegeneration in Parkinson's Disease

CNS Neuroscience &Therapeutics, Volume 32, Issue 3, March 2026.
This study is the first to demonstrate that SYNGR3 interacts with α‐synuclein and identify SYNGR3 as a key trigger of α‐synuclein aggregation in Parkinson's disease. Targeting SYNGR3 mitigates neurotoxicity and motor deficits, highlighting its promising potential as a therapeutic strategy.
Xin Wang, Jiaolong Yang, Ziku Wang, Zhichao Liu, Wei Tan, Zhentao Zhang   +5 more
wiley   +1 more source

SNCA-AS1 in aging and Parkinson’s disease

Aging, 2022
Carelli, Stefana, Rey, Federica, Cereda, Cristina   +2 more
openaire   +2 more sources

Molecular imprinting for neurology: Materials, applications, and limitations

Ibrain, Volume 12, Issue 1, Page 3-37, Spring 2026.
Molecularly imprinted materials: diagnostic, therapeutic and research applications in neurology. Molecularly imprinted materials offer high specificity and affinity for target molecules in neurological applications. This review highlights their synthesis, characterisation, and use in diagnostics, research and therapeutics.
Xiaohan Ma, Yingqi Ma, Claudia Marino, Alessandro Poma   +3 more
wiley   +1 more source